Felicitas Rataj
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 03, 2022
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Journal: Blood cancer journal
Published: March 24, 2021
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: February 13, 2021
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Journal: Leukemia
Published: June 17, 2020
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Journal: Nature biomedical engineering
Published: May 11, 2020
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 03, 2018
Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.
Journal: Oncogene
Published: July 04, 2018
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Journal: British journal of cancer
Published: May 15, 2018
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.
Journal: Frontiers in oncology
Published: March 29, 2018
Last Updated: 09/26/2026